Autopsy report · NCT04952519

Efficacy of Amantadine Treatment in COVID-19 Patients

“The annual analysis did not show the efficacy of the investigational medicinal product in this application, therefore the study was not continued.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Ran for about 11 months before it stopped.
• 193 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Noblewell

Sponsor type

Industry

Conditions

Patients With Moderate or Severe COVID-19

Interventions

Amantadine

Participants

193

Sites

12

Countries

Poland

Trials that died the same way

• DASH - Decision Making in Adolescent Sexual Health
  “This research was not conducted at UNM \& not Applicable Clinical Trial.” (70% match in meaning)
• A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
  “One of the drugs for the study is not commercially available.” (67% match in meaning)
• Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19
  “The study was not approved by the Italian Medicines Agency (AIFA).” (66% match in meaning)
• A Pilot Study of Candesartan as a Treatment for Cocaine Dependence
  “Results of interim efficacy analysis showed results were not promising.” (65% match in meaning)
• Iontophoresis in Psoriasis
  “FDA did not provide approval of the use of the drug for the study” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.